Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer
Alberto Martini(The University of Texas MD Anderson Cancer Center), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Markus Graefen(Eppendorf (Germany)), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Giorgio Gandaglia(Vita-Salute San Raffaele University), Rafael Salas(Instituto Venezolano de Investigaciones Científicas), Paolo Gontero(Fondazione Ricerca Molinette), Derya Tilki(Koç University), Burkhard Kneitz(Universitätsklinikum Würzburg), Vito Cucchiara(IRCCS Ospedale San Raffaele), Martin Spahn(Universitätsklinikum Würzburg), Marco Bianchi(Université de Montréal), Francesco Montorsi(Vita-Salute San Raffaele University), R. Jeffrey Karnes(Mayo Clinic), Emanuele Zaffuto(Ospedale di Circolo e Fondazione Macchi), Piotr Chłosta(Jagiellonian University), Christian Gratzke(University Medical Center Freiburg), Vincenzo Mirone(University of Naples Federico II), Henk G. van der Poel(Amsterdam University Medical Centers)
Cited by 21
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
|The Lancet|2012|864
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694